Immunomedics (NSDQ:IMMU) said it landed an exclusive global licensing agreement with Seattle Genetics (NSDQ:SGEN) for Immunomedics’ antibody-drug conjugate, IMMU-132, for the treatment of solid tumors. The deal could potentially bring in $2 billion plus royalties for Immunomedics. According to the deal, Seattle Genetics is responsible for developing, funding, manufacturing and commercializing IMMU-132. The Washington-based company will […]
